Whitehawk Therapeutics (WHWK) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 11, 2026, with voting on director elections, executive compensation, and auditor ratification.

• Stockholders of record as of April 17, 2026, are entitled to vote; 49,428,177 shares outstanding.

• The company completed a major divestiture in March 2025, selling its FYARRO business and changing its name.

• A $100 million PIPE financing closed in March 2025, with participation from directors, officers, and major holders.

Voting matters and shareholder proposals

• Three Class III directors are nominated for election to serve until 2029.

• Advisory vote on executive compensation (say-on-pay) is included.

• Ratification of BDO USA, P.C. as independent auditor for 2026 is proposed.

• No other business is currently anticipated for the meeting.

Board of directors and corporate governance

• Board consists of nine members, divided into three staggered classes.

• Seven of nine directors are independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Board leadership is separated between the Chairman and CEO roles.

• Corporate governance guidelines and a code of business conduct and ethics are in place.